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Objective. To assess the eﬃcacy and the eﬀect on Qol of solifenacin for the treatment of OAB in MS patients. Patients and Methods.
Thirty MS patients suﬀering from OAB were treated with solifenacin 5/10mg for 8 weeks. The first 4 weeks patients received
solifenacin 5mg. At week 4 patients could request a dose increase to 10mg. The eﬃcacy was evaluated at 8 weeks. Results. After
4 weeks of treatment, 28 patients reported acceptable or no side eﬀects. 17 continued the study with the 10mg dosage, and 11
stayed on 5mg solifenacin. Two patients withdrew from the study due to side eﬀects. Solifenacin 5/10mg for 8 weeks resulted
in a significant decrease in number of micturitions and number of pads used per day compared to baseline. Also the severity
of urgency prior to voiding decreased significantly, and an increase was seen in the volume per void. Twenty out of 30 patients
chose to continue solifenacin therapy after termination of the study. The majority of patients reported global QoL improvement.
Conclusions. Solifenacin is eﬀective in the treatment of MS patients with OAB symptoms. This is the first study with solifenacin in
a specific neurogenic patient group with a neurogenic disease-specific QoL outcome measure (MS-QoL 54).
1. Introduction
Solifenacin is a once-daily oral antimuscarinic agent that
has been available in The Netherlands since September 2004
for the treatment of overactive bladder (OAB). The eﬃcacy
and safety of solifenacin has already been demonstrated in
randomised, double-blind placebo controlled studies [1, 2].
However, the eﬃcacy of solifenacin inmultiple sclerosis (MS)
patients with symptoms of OAB is unclear, since underlying
neurological disease was an exclusion criterion in previous
clinical studies. The aim of the present study was to assess
the eﬃcacy of solifenacin in MS patients with symptoms of
OAB. To our knowledge to date this is the first and only study
in which the eﬃcacy of solifenacin for symptoms of OAB is
evaluated in a neurogenic patient population.
2. Patients and Methods
This is a prospective, open-label study to assess the eﬃcacy
and eﬀect on quality of life of solifenacin 5/10mg for
8 weeks in the treatment of MS patients with symptoms
of OAB. The study protocol was approved by the local
ethics committee of the University Medical Centre Nijmegen
(CMO no. 2004/194). Patients provided written informed
consent before enrolment.
Men and women with a classifiedMS diagnosis according
to the criteria of McDonald et al. [3] and symptoms of OAB
were eligible for screening and study enrolment. Inclusion
and exclusion criteria are listed in Table 1. None of the
patients experienced a clinical relapse of their MS within
3 months prior to inclusion. Patients were evaluated at
the outpatient clinic for symptoms of OAB by history,
uroflowmetry, and determination of residual urine. Most
patients underwent a urodynamic workup, but this was not
mandatory for inclusion in the protocol.
All medication that could influence bladder function was
stopped at least 2 weeks prior to treatment or continued
with no dose changes during the study. Patients were not
allowed to use other antimuscarinic drugs prescribed for
bladder dysfunction 2 weeks prior to or during the study. All
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Table 1
Inclusion criteria (patients were eligible if all of the following applied)
(1) Classified MS diagnosis
(2) Written informed consent has been obtained
(3) Patients are willing and able to complete the micturition diary correctly
(4) Complaints of OAB
(a) Urgency/Frequency (micturition frequency > 8/day)
(b) Urge incontinence (involuntary loss of urine after a sensation of urge)
Exclusion criteria (patients would be excluded from participation if any of the following apply)
(1) Significant postvoid residual volume (PVR >200mL)
(2) Evidence of a urinary tract infection, chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation
therapy, or previous or current malignant disease of the pelvic organs
(3) Uncontrolled narrow angle glaucoma, urinary or gastric retention, or any other medical condition which in the opinion of the
investigator makes the use of anticholinergics contra-indicated
(4) Non-drug treatment including electrostimulation therapy or start of a bladder training program during the 12 weeks prior to
or during the study
(5) Use of drugs intended to treat urinary incontinence
(6) Known or suspected hypersensitivity to other anticholinergics or lactose
(7) Any clinical significant condition, which in the opinion of the investigator makes the patient unsuitable for the trial
(8) Pregnancy or the wish to become pregnant during the study
methods, units, and definitions used in this study were done
according to ICS standards [4].
At baseline patients were evaluated by 72-hour voiding
diaries, as well as an MS-specific quality of life questionnaire
(MS-QoL 54). The MS-QoL 54 is a multidimensional health-
related quality of life measure that combines both generic
and MS-specific items to a single instrument [5].
In the voiding diary the voiding frequency, voided vol-
ume per void, severity (degree) of urgency prior to any void,
number of incontinence periods, severity of incontinence
periods, and number of pads used were recorded. The degree
of urgency was described on a scale of 0–3 (i.e., 0, no urge to
void; 1, moderate urge to void; 2, normal urge to void that
can still be suppressed; 3, severe urge to void that cannot be
suppressed). The severity of urine loss was described on a
scale of 0–3 (i.e., 0, no urine loss; 1, loss of some drops; 2,
loss of a small amount; 3; severe loss possibly leading to a
change of clothes).
Patients that met all inclusion criteria, and none of
the exclusion criteria received solifenacin 5/10mg for 8
weeks. All patients received solifenacin 5mg once daily in
the the first 4 weeks. At week 4, patients could continue
5mg solifenacin treatment for another 4 weeks or request
a dose escalation to 10mg once daily in case of subjective
insuﬃcient eﬃcacy and no or acceptable side eﬀects.
Both solifenacin 5 and 10mg once daily have been shown
to be eﬀective and well tolerated for treating symptomatic
OAB [6]. A starting dose of 5mg solifenacin was chosen
because of the somewhat favourable eﬃcacy/side-eﬀect ratio
compared to 10mg solifenacin.
After a total treatment period of 8 weeks the eﬃcacy of
solifenacin was evaluated by 72-hour voiding diary and MS-
QoL 54. Global patient perception was assessed by enquiring
patient satisfaction and the patients’ desire to continue the
treatment.
Primary endpoints were defined as change from baseline
in mean number of micturition per 24 hours, change from
baseline in mean voided volume per void, and change from
baseline in number of incontinence episodes per 24 hours
and number of pads used per 24 hours. Change in quality
of life (QoL), as measured with the MS-QoL 54, was a
secondary endpoint.
Changes from baseline to endpoint were subjected to the
Wilcoxon signed-ranks test.
The quality of life questionnaires were compared using
the test for paired samples correlations (paired t-test).
3. Results
Between January and July 2005, 30 patients with MS and
OAB symptoms were enrolled in this clinical study. All
patients (12 men and 18 women) were diagnosed with OAB.
Nine patients suﬀered from “OAB-dry” and 21 of “OAB-
wet” Seven patients had received antimuscarinic therapy in
the past without the desired eﬀect. Twenty-three patients
have not been treated with antimuscarinic agents prior to
inclusion in the protocol. No patients had received other
therapy than oral antimuscarinics for the OAB symptoms
prior to the study.
After 4 weeks of treatment with solifenacin 5mg, 28
patients reported acceptable or no side eﬀects. Two patients
withdrew from the study due to adverse events (gastroin-
testinal complaints and skin rash.) Both adverse events fully
disappeared within days from discontinuation of the therapy.
Of the remaining 28 patients, 11 patients (39%) chose to
continue treatment with the 5mg dosage. Seventeen (61%)
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Table 2
Baseline (IQD) n = 30 After 8 weeks of treatment
(IQD) n = 28 Wilcoxon signed ranks Test
Median frequency/day 11.7 (9.3–13.4) 9.5 (6.9–10.9) P = .000
Median volume voided/void 121.9 (103.1–152.9) 155.3 (103.1–198.2) P = .000
Median incontinence episodes/day 1.3 (0.0–2.7) 0.2 (0.0–1.7) P = .360
Median no. pads used/day 2.0 (0.0–3.4) 1.0 (0.0–2.0) P = .010
Median severity of urine loss (0–3; daily
added score)
1.2 (0.0–5.0) 0.3 (0.0–2.8) P = .053
Median degree of urgency prior to voiding
(0–3; daily added score)
36.3 (28.8–47.3) 23.7 (18.0–31.0) P = .000
patients requested a dose escalation to 10mg solifenacin due
to subjective insuﬃcient eﬃcacy.
Evaluation of the voiding diaries after 8 weeks of treat-
ment compared to baseline showed a significant decrease in
median number of micturitions (−2.2 episodes/24 hours,
P < .0001) and number of pads used per 24 hours (−1,0
pads/24 hours, P = .010). Also the degree of urgency
prior to voiding decreased significantly (−12.6, P < .0001).
Additionally a significant increase with 33mL (P < .0001)
was seen in the median voided volume per void. Whilst the
median number of incontinence episodes per 24 hours and
themedian severity of urine loss improved numerically, these
changes were not statistically significant (Table 2). This could
be due to the low number of patients that were incontinent
at study baseline.
Although many patients thus reported a subjective
improvement in QoL, this was not apparent when analysing
theMS-QoL 54. Only one of the subscales, health perception,
showed a borderline significant increase of 0.8 points (P =
.041). All other MS-QoL 54 subscales detected no significant
diﬀerences from baseline to end of study (Table 3).
Global patient perception evaluation showed that 22 out
of 30 patients (73%) chose to continue solifenacin therapy
after the study, due to beneficial eﬀects. Six patients (20%)
chose to terminate the use of the drug because of lack of
eﬀect. Only in 2 out of 30 (7%) patients the reason for
discontinuation of therapy was side eﬀects.
4. Discussion
Lower urinary tract symptoms are common in MS. Up
to 90% of patients have voiding complaints at some time
during the course of the disease, especially with a disease
duration longer than 10 years [7]. Themost common voiding
complaints are urgency, occurring in 24–86%, and urge
incontinence, reported in 34–72% of patients [8].
Unlike the bladder dysfunction that follows spinal cord
injury and causes life-threatening upper urinary tract con-
ditions, MS very rarely causes severe upper urinary tract
involvement but rather results in morbidity that influences
the quality of life [9].
Anticholinergic agents are commonly used in the man-
agement of the OAB. For more than 30 years oxybutynin
has been the drug of choice in patients with a neurogenic
cause of OAB. Randomised controlled studies comparing
oxybutynin to other antimuscarinic agents in neurogenic
patients date from the late 1980s and early 1990s [10, 11].
A lot of neurogenic patients need a higher dose to achieve
clinical eﬃcacy [12]. With the introduction of tolterodine
in 1999 a new antimuscarinic agent was added to the
management options op OAB. Tolterodine is said to be
equally eﬀective compared to oxybutynin, but with a better
side-eﬀect profile [13]. Ethans et al. published the first
randomised, controlled study comparing these two agents
in neurogenic patients. It consisted of merely 10 patients
[14]. In 2004 solifenacin was introduced for the treatment of
OAB symptoms. In all pivotal studies neurogenic causes of an
overactive bladder were considered an exclusion criterion [6,
15]. Therefore the eﬃcacy of solifenacin in patients suﬀering
from lower urinary tract dysfunction due to MS (or any
other neurogenic cause) is unclear. However, OAB symptoms
are very common in MS patients, and antimuscarinics
are frequently prescribed, although the evidence for this
indication is low. Therefore, even clinical studies with a
relatively simple design are valuable in a specific group like
MS patients.
Most of the time neurogenic patients are excluded
from registration studies because they respond diﬀerently to
medical treatments or they deal diﬀerently with common
primary endpoints in OAB studies such as micturition
frequency. When a wheelchair-bound patient has to tell
you how many times he or she goes to the toilet per day,
the answer will be highly dependent, amongst others, on
environmental factors such as the availability of proper
wheelchair toilets. Moreover MS is a progressive disease, so
the clinical endpoint may diﬀer from baseline to end of study
even without intervention. The issue is that we do not have
objective parameters to define a stable patient, apart from
that MS patients are not a homogeneous group and that they
may have all kinds of disabilities.
This study shows that solifenacin is eﬀective in the
treatment ofMS patients with OAB symptoms when assessed
by means of 72-hour voiding diaries. Significant improve-
ments were observed on severity of urgency, frequency
and urge incontinence and number of pads used in 24
hours. Also subjective improvements evaluated by means
of the global patient perception question suggested that
patients were satisfied with the eﬃcacy of solifenacin on their
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Table 3
N = 28 Mean Std. deviation Std. error mean P value
Physical health
T1 25.9 19.7 4.8
.191
T2 27.4 22.9 5.6
Role limitation (physical)
T1 25.0 35.4 8.6
.173
T2 32.4 35.1 8.5
Role limitation (emotional)
T1 68.6 39.9 9.7
.985
T2 62.7 42.3 10.3
Pain
T1 68.2 28.9 7.0
.963
T2 82.3 23.4 5.7
Emotional well-being
T1 77.6 20.2 4.9
.761
T2 72.7 13.2 3.2
Energy
T1 47.5 22.5 5.5
.740
T2 47.3 18.0 4.4
Health perception
T1 36.2 18.2 4.4
.041
T2 37.4 15.6 3.8
Social function
T1 54.9 12.9 3.1
.631
T2 58.8 12.3 3.0
Cognitive function
T1 66.5 26.9 6.5
.669
T2 76.5 19.0 4.6
Health distress
T1 67.1 21.2 5.1
.517
T2 69.4 21.4 5.2
Sexual function
T1 44.6 31.3 7.6
.203
T2 51.0 32.1 7.8
Change in health
T1 27.9 26.3 6.4
.409
T2 36.8 28.1 6.8
Sexual satisfaction
T1 35.3 36.5 8.9
.394
T2 44.1 37.0 9.0
Overall QoL
T1 58.2 13.2 3.2
.725
T2 57.7 12.0 2.9
MS QoL54 (physical)
T1 44.3 15.3 3.7
.446
T2 48.4 15.4 3.7
MS QoL54 (mental)
T1 68.8 20.6 5.0
.863
T2 67.7 17.5 4.2
MS QoL54 (total)
T1 113.1 33.9 8.2
.955
T2 116.1 30.9 7.5
symptoms. 73% of patients wanted to continue therapy due
to favourable results. We recognize that the study design is
limited by the absence of a control group. It would be useful
to do a head to head comparison in a randomized controlled
trial in the future.
The eﬀects on QoL, measured with the MS-QoL 54, were
not apparent. The developers of the MS-QoL 54 utilized the
Short Form 36 (SF-36) as the generic component to which 18
items were added to tap MS-specific issues [5]. It contains 54
questions distributed among 12 subscales (with 2 summary
scores) and 2 single-itemmeasures. TheMS-QoL 54 contains
only one question concerning bladder and/or bowel function
(no. 51) and there is a subscale that specifically measures
urological function/perception. Question 51 of the MS-QoL
54 informs about the degree in which patient were limited
in their social activities during the last 4 weeks as result of
their bladder and/or bowel dysfunction. We hypothesize that
for this reason the MS-QoL 54 may be not sensitive enough
to detect changes in the QoL due to lower urinary tract
functioning. The domains of physical health, physical role
limitations, health, perception and sexual function do show
a trend towards increased QoL. Since lower urinary tract
symptoms cause a substantial decrease in quality of life also
in MS patients we expected that the improvement in lower
urinary tract symptoms would have caused improvements in
other domains of the MS-QoL 54 as well [16]. Therefore we
think that the study is too small to show this eﬀect. Urological
problems are of major importance in the lives ofMS patients,
so we suggest that this domain should be incorporated in an
MS-specific quality of life measuring instrument.
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5. Conclusion
Solifenacin is eﬃcacious in treating OAB symptoms in
MS patients. Solifenacin significantly improved frequency,
severity of urgency, volume voided, and number of pads used
per 24 hours.
The MS-QoL 54 showed no significant changes, other
than a modest improvement in one of the subscales. Possibly,
MS-QoL 54 is not specific enough to detect changes in OAB
symptoms in an MS patient population. Further randomised
clinical studies with antimuscarinics in this specific patient
group are warranted.
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